Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab, LM-302, S-1, and Paclitaxel in Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
NCT06519591Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Feb 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab, tpx-4589, tegafur and paclitaxel in gastric cancer (GC), sponsored by Ruijin Hospital. Primary endpoint: 1-year survival rate at 24 months. Started Feb 2025; status: recruiting.
02
Drugs
cadonilimabtpx-4589tegafurpaclitaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06519591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06519591.